Results from a recent study suggest that considering nearby variants can improve the accuracy of neoantigen selection, resulting in better personalized vaccines for patients.
The companies will use Natera's Signatera circulating tumor DNA assay to assess response to NEO-PV-01, a clinical trial-stage neoantigen cancer vaccine.
The grant will support the consortium's ongoing efforts to clinically validate data analysis software for monitoring treatment responses to cancer vaccines.
The Universal Influenza Vaccine Initiative, led by Vanderbilt and the Human Vaccines Project, has turned to omics and AI to create more effective flu vaccines.
Neon Therapeutics is sponsoring a Phase Ib trial of neoantigen-based vaccines in combination with anti-PD-1 treatment in melanoma, lung cancer, and bladder cancer.
